PMID: 25763586Mar 13, 2015Paper

The current pharmacotherapy of pulmonary arterial hypertension

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
Katarzyna Betkier-LipińskaAndrzej Cwetsch

Abstract

Pulmonary arterial hypertension (PAH) is a chronic, serious disease caused by remodeling of small pulmonary vessels, which leads to increase of pulmonary resistance, right heart failure and death. The 1990ths of XX century are the beginning of dynamic research into the pathophysiology and treatment of this disease. Actually, the goal oriented therapy based on three main metabolic pathways includes: prostacyclin's analogues, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Applying this therapy, according to ESC guidelines has prolonged significantly the survival in the group of patients with PAH. Due to the high cost of the therapy, there has been created the national therapeutic program in Poland. It assures the real possibility of therapy for patients with PAH from the third FC WHO.

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The Cochrane Database of Systematic Reviews
Chao LiuKunshen Liu
The Cochrane Database of Systematic Reviews
Chao LiuKunshen Liu
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
Katarzyna Betkier-LipińskaAndrzej Cwetsch
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Yan-Ping Yu, Xian-Mei Huang
© 2021 Meta ULC. All rights reserved